<?xml version='1.0' encoding='utf-8'?>
<document id="22235953"><sentence text="Evaluation of a wireless handheld medication management device in the prevention of drug-drug interactions in a Medicaid population." /><sentence text="With the passage of the Health Information Technology for Economic and Clinical Health (HITECH) Act, widespread adoption of certain health information technologies, such as electronic health records (EHRs) and electronic prescribing (e-prescribing), is imminent" /><sentence text=" Drug-drug interaction (DDI) screening and medication history information are commonly incorporated into health information exchange systems to improve medical decision making, safety, and quality of care, but the value of these features is unclear" /><sentence text="" /><sentence text="To evaluate the effect of providing access to an early generation electronic medication management program with medication history accessible to prescribers via a wireless handheld personal digital assistant (PDA) device on the incidence of potential DDIs (i" /><sentence text="e" /><sentence text=", DDIs that may or may not cause patient harm)" /><sentence text="" /><sentence text="This study employed a retrospective pre-intervention/post-intervention study design with a comparison group to evaluate the effectiveness of a wireless handheld medication management program in preventing serious potential DDIs" /><sentence text=" Licensed prescribers in a state Medicaid program who wrote prescriptions during the period from August 2003 through June 2006 were included in this study" /><sentence text=" The intervention (PDA) group consisted of clinicians who requested and were granted access to the wireless handheld device containing prescription drug history between August 1, 2004, and June 30, 2005" /><sentence text=" Initially the device contained 100-day patient-specific medication history, but other functionalities were added during the study period including the ability to check for drug-drug interactions and e-prescribing" /><sentence text=" The comparison group consisted of prescribers who sent a request to obtain, but did not receive, the wireless handheld device during the same time period" /><sentence text=" Baseline prescribing patterns of 25 previously identified clinically important potential DDIs were assessed over two 12-month periods, one period prior to (baseline) and one period after (follow-up) an index date (date of device deployment for PDA group; date of request for comparison group)" /><sentence text=" A random-effects negative binomial model was used to analyze the primary outcome, the number of potential DDIs per prescriber per 12-month time period" /><sentence text=" A secondary outcome of interest, the likelihood that a prescriber would prescribe at least 1 potentially interacting medication pair during the baseline and follow-up periods, was analyzed using a random-effects logistic model" /><sentence text="" /><sentence text="A total of 1,615 prescribers constituted the PDA group, and 600 prescribers made up the comparison group"><entity charOffset="45-48" id="DDI-PubMed.22235953.s18.e0" text="PDA" /></sentence><sentence text=" Prescribers in the 2 groups were significantly different in their specialty practice areas (P less than 0" /><sentence text="001), number of pharmacy claims at baseline (P less than 0" /><sentence text="001), and the likelihood of prescribing at least 1 potential DDI combination during the 1-year baseline period (P=0" /><sentence text="003)" /><sentence text=" However, the prescriber groups were similar in their average age (P=0" /><sentence text="241) and geographic location (P=0" /><sentence text="181)" /><sentence text=" The most widely prescribed potential DDIs included those involving warfarin with nonsteroidal anti-inflammatory drugs (NSAIDs) and thyroid hormones" /><sentence text=" The median number of patient medication history updates requested per PDA group prescriber during follow-up was 24 (range 0 to 1,073)"><entity charOffset="71-73" id="DDI-PubMed.22235953.s27.e0" text="PDA" /></sentence><sentence text=" At baseline, 1,104 (68" /><sentence text="4%) of the PDA group and 449 (74"><entity charOffset="11-14" id="DDI-PubMed.22235953.s29.e0" text="PDA" /></sentence><sentence text="8%) of the comparison group had no potential DDIs" /><sentence text=" During the next year, 1,131 (70" /><sentence text="0%) and 462 (77" /><sentence text="0%) of the PDA group and comparison group, respectively, had no DDIs"><entity charOffset="11-14" id="DDI-PubMed.22235953.s33.e0" text="PDA" /></sentence><sentence text=" The incidence rate ratio was 1" /><sentence text="01 (95% CI=0" /><sentence text="87-1" /><sentence text="17) for the PDA group relative to the comparison group for change in number of potential DDIs"><entity charOffset="12-14" id="DDI-PubMed.22235953.s37.e0" text="PDA" /></sentence><sentence text=" In the logistic regression model, the odds of prescribing at least 1 potential DDI did not significantly differ by group (odds ratio=1" /><sentence text="26, 95% CI=0" /><sentence text="96-1" /><sentence text="66)" /><sentence text=" These results indicate that there was no significant difference between the intervention and comparison group with regard to the change in the rate of potential DDIs between the baseline and follow-up periods" /><sentence text="" /><sentence text="A stand-alone medication management program in a wireless PDA device was not frequently used by most prescribers to update patient medication histories and was not associated with a reduction in the rate of prescribing potentially clinically important DDIs"><entity charOffset="58-60" id="DDI-PubMed.22235953.s44.e0" text="PDA" /></sentence><sentence text="" /></document>